Clinical trials
Cholangiocarcinoma clinical trials
Below are recruiting cholangiocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 185 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06956716RecruitingPhase 1/Phase 2
Personalized mRNA vaccine for advanced bile duct cancer
This trial tests a personalized mRNA vaccine made from your tumor's genetic information. It's for people with advanced bile duct cancer that hasn't been treated yet, to see if it can help their immune system fight the cancer.
Hangzhou, ZhejiangAges 18–75 - NCT05285358RecruitingPhase 1
Aerosol chemo plus standard drugs for bile duct and gallbladder cancer
This trial tests a new way to give the drug paclitaxel directly into your belly as a mist, along with two standard chemo drugs given through your veins, for bile duct or gallbladder cancer that has spread to the lining of the belly. The goal is to see if this approach can better control the cancer in the belly.
Duarte, CaliforniaAges 18 years+ - NCT06607302Recruiting
Study of ivosidenib for bile duct cancer with IDH1 mutation
This study is looking at how well the drug ivosidenib works for people with a certain type of bile duct cancer (cholangiocarcinoma) that has a specific change in the IDH1 gene. It is for people whose cancer has spread or cannot be removed by surgery and who have already tried at least one other cancer treatment.
AugsburgAges 18 years+ - NCT06192797RecruitingPhase 2
Combination therapy for unresectable bile duct cancer
This trial tests a combination of three treatments—a liver-directed chemotherapy infusion (HAIC), a targeted therapy pill (lenvatinib), and an immunotherapy (pucotenlimab)—to try to shrink bile duct cancers that cannot be surgically removed. The goal is to make the cancer surgically removable or to control it for as long as possible.
Wuhan, HubeiAges 18 years+ - NCT04078230Recruiting
Extending lymph node removal during liver tumor surgery
This study looks at whether removing more lymph nodes while surgically removing an intrahepatic cholangiocarcinoma (bile duct cancer in the liver) improves outcomes. It may help by better checking and treating possible microscopic spread to lymph nodes.
Baltimore, MarylandAges 18–80 - NCT04299581RecruitingPhase 2
Freezing treatment plus immunotherapy for advanced bile-duct cancer
This Phase 2 trial tests whether freezing part of the liver tumor (cryoablation) combined with an immunotherapy drug called anti–PD-1 can shrink advanced bile-duct cancer that can’t be removed by surgery. It may help control the cancer after prior treatments have stopped working.
ShanghaiAges 18 years+ - NCT04340986Recruiting
Group study for bile duct or liver cancer patients
This study follows people with bile duct cancer or certain liver cancers to better understand their disease. You might be included if you meet the diagnosis and basic participation requirements.
ParisAges 18 years+ - NCT04556214Recruiting
Liver transplant test for certain bile duct cancers
This trial studies whether a liver transplant can help people with a non-removable type of bile duct cancer in the liver. To be eligible, the cancer must be in the liver only (no spread), and you typically must already have had at least 6 months of treatment before being listed for transplant.
OsloAges 18 years+ - NCT04891289RecruitingPhase 2
Gemcitabine and oxaliplatin with a chemotherapy pump for bile duct cancer
This Phase 2 study tests gemcitabine plus oxaliplatin chemotherapy, and whether adding a chemotherapy pump (with floxuridine and dexamethasone) delivered to the liver improves outcomes. It is for people whose intrahepatic cholangiocarcinoma cannot be removed with surgery.
Bethesda, MarylandAges 18 years+ - NCT05874414RecruitingPhase 1/Phase 2
Combination therapy for advanced KRAS-mutated bile duct cancer
This trial tests a new combination of two drugs, GNS561 and trametinib, for people with advanced bile duct cancer (cholangiocarcinoma) that has a specific genetic change called a KRAS mutation. The goal is to see if this combination can shrink tumors or slow the disease after prior chemotherapy.
Los Angeles, CaliforniaAges 18 years+ - NCT04954781RecruitingPhase 2
Chemo plus immunotherapy for advanced bile duct liver cancer
This Phase 2 trial tests whether a procedure called TACE combined with the immunotherapy drug tislelizumab can shrink advanced bile duct liver cancer and help you live longer. It is for people whose cancer cannot be removed and has progressed after at least one prior treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04993131Recruiting
Liver transplant for non-surgical bile duct cancer
This trial studies liver transplantation for people with a specific type of bile duct cancer near the liver that cannot be safely removed by surgery. It aims to improve outcomes by offering a transplant after the cancer responds to chemotherapy and spread has been ruled out on scans.
OsloAges 18 years+ - NCT05184400Recruiting
Find new blood or tumor markers for bile duct and gallbladder cancer
This study looks for new ways to measure cancer-related “biomarkers” (signals in blood or tumor samples) in people with bile duct cancer or gallbladder cancer. The goal is to improve how these cancers are identified and tracked, which could help doctors make better treatment decisions.
Herlev, CopenhagenAges 18 years+ - NCT05223816RecruitingPhase 2
Tested drug shots for advanced liver and bile duct cancers
This Phase 2 study tests a drug called VG161 given by injection into liver tumors, either alone or together with nivolumab. It aims to see how well it works and whether it is safe for people with advanced hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC).
Phoenix, ArizonaAges 18 years+ - NCT05430698RecruitingPhase 2
PD-1 antibody after surgery for bile duct cancer
This Phase 2 trial studies whether adding a PD-1 antibody plus gemcitabine/oxaliplatin (GEMOX) after surgery can lower the chance of the cancer coming back in perihilar cholangiocarcinoma. It’s for people who have had surgery with no tumor left at the cut edges, but lymph nodes showed cancer under the microscope.
Guangzhou, GuangdongAges 18–75 - NCT05532059RecruitingPhase 2
Test lenvatinib, tislelizumab, and chemotherapy for bile duct cancer
This Phase 2 trial tests a combination of lenvatinib, an immunotherapy drug (tislelizumab), and chemotherapy (gemcitabine plus cisplatin) for advanced bile duct cancer that cannot be removed with surgery. It aims to see whether this treatment can shrink tumors and improve outcomes, especially for people who have not yet had immunotherapy.
Hangzhou, ZhejiangAges 18–85 - NCT05546372Recruiting
Radiofrequency ablation to treat blocked bile ducts from bile cancer
This study tests whether radiofrequency ablation can improve treatment for people who have a malignant (cancer-related) blockage of the bile ducts near the liver (perihilar cholangiocarcinoma). It’s for patients who are not good candidates for curative surgery and who need bile-duct drainage using a specific stent (uSEMS).
AmsterdamAges 18 years+ - NCT05568680RecruitingPhase 1
Early trial of SynKIR-110 for certain ovarian and lung-lining cancers
This Phase 1 study tests SynKIR-110 in people with certain advanced cancers that have come back or continued growing after prior treatments. It aims to find out if the treatment is safe and how the body responds, including early signs of effectiveness.
Tampa, FloridaAges 18 years+ - NCT05678270RecruitingPhase 2
ICP-192 for FGFR2 fusion bile duct cancer that spread
This Phase 2 trial tests a medicine called ICP-192 in people with intrahepatic bile duct cancer that cannot be removed with surgery and has spread. It is for tumors that have an FGFR2 fusion/rearrangement, especially after prior chemotherapy stopped working.
Hefei, AnhuiAges 18 years+ - NCT05727176RecruitingPhase 2
Futibatinib for advanced bile duct cancer with FGFR2 changes
This trial tests futibatinib, a targeted pill, in people with advanced (unresectable) or metastatic bile duct cancer that has an FGFR2 fusion or rearrangement. It may help shrink tumors after standard chemotherapy has stopped working.
La Jolla, CaliforniaAges 18 years+ - NCT05967182RecruitingPhase 2
Pembrolizumab plus chemo before or around liver surgery
This trial tests whether pembrolizumab combined with gemcitabine and cisplatin given around the time of surgery can improve outcomes for people with high-risk, potentially operable intrahepatic cholangiocarcinoma (bile duct cancer in the liver). It may help by strengthening the immune system while also treating the cancer with chemotherapy.
Houston, TexasAges 18 years+ - NCT06098547Recruiting
Liver transplant for bile duct cancer that can't be removed
This trial tests if a liver transplant can help people with a certain type of bile duct cancer (intrahepatic cholangiocarcinoma) that cannot be surgically removed. You must have had at least six months of chemotherapy and your cancer must be stable or smaller before you can be listed for a transplant.
PadovaAges 18–70 - NCT06125769Recruiting
Liver transplant for hard-to-treat bile duct cancer
This trial studies liver transplantation to treat a specific bile duct cancer (perihilar cholangiocarcinoma) that cannot be removed by surgery. It aims to see if a transplant can help when standard chemotherapy has kept the cancer stable.
Padova, PADOVAAges 18–70 - NCT06199895RecruitingPhase 2
Study of paclitaxel for patients with taxane-resistant solid tumors
This trial tests paclitaxel given as tiny micelle particles for people whose cancer (pancreatic, bile duct, lung, stomach, esophagus, or breast) stopped responding to taxane chemotherapy or did not shrink. The goal is to see if this treatment can help when standard taxanes no longer work.
Wuhan, HubeiAges 18 years+
Hear when a new Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cholangiocarcinoma?
- Yes. Clin2 currently lists 185 recruiting cholangiocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cholangiocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cholangiocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.